

Costs of Illness for Six Major Health Conditions Among Older Adults

George Van Houtven, Ph.D.¹

Amanda A. Honeycutt, Ph.D.¹

Boyd Gilman, Ph.D.¹

Nancy T. McCall, ScD.¹

Wanda W. Throneburg, B.S.¹

Kathy E. Sykes, M.A.²

November 30, 2004

¹ RTI International. (RTI International is a trade name of Research Triangle Institute.)

² U.S. Environmental Protection Agency, Aging Initiative

Costs of Illness for Six Major Health Conditions Among Older Adults

ABSTRACT

Objectives. This study estimates the annual cost burden associated with six major illnesses among the aged 65 or older population in the United States: chronic lung disease, ischemic heart disease, stroke, lung cancer, pneumonia, and gastrointestinal illness. These illnesses were selected because of their relatively high impact among older populations and because they include environmental exposures as a significant risk factor.

Methods. A prevalence-based cost-of-illness approach was applied. Medical costs were estimated from Medicare claims data, and drugs costs from Medical Expenditures Panel Survey data. Indirect costs were estimated using a human capital approach. Morbidity-related productivity effects were estimated through regression analyses of National Health Interview Survey data, and mortality rates were based on National Vital Statistics Reports. All productivity losses were valued using dollar estimates of average age-specific labor earnings and household production.

Results. Total estimated aggregate costs range from \$0.5 billion (gastrointestinal illness) to almost \$60 billion (ischemic heart disease). The combined costs of these conditions among the aged 65 or older population in 2000 were almost \$135 billion.

Discussion. With the expectation that costs of these illnesses will increase significantly as population ages, priority should be given to prevention strategies, such as improvements in environmental quality.

INTRODUCTION

Since the early 1990s, health care spending in the United States has increased dramatically, even though the percentage of the population aged 65 or older has remained relatively stable. Between 1990 and 2002, per capita expenditures on health care grew by 45% in real terms, while percent of population aged 65 or older remained at roughly 12.5%. However, the aged 65 or older population is expected to increase significantly over the next decades, and this demographic shift is certain to put additional upward pressure on aggregate health costs and on the growing demand for health care services. To promote a better understanding of the health-related economic implications of an aging population, this analysis estimates the total annual cost burden associated with six major illnesses among the aged 65 or older population in the United States.

The six categories of illness selected for this analysis are chronic lung disease (CLD), ischemic heart disease (IHD), stroke, lung cancer, pneumonia, and gastrointestinal illness (GI). These conditions were selected for several reasons. First, each has a relatively high rate of prevalence among older populations (compared with younger populations) and is a major cause of death (except GI) among persons aged 65 or older. Therefore, they are major contributors to the total costs of illness in this age group. Second, the costs of these illnesses have rarely, if ever, been specifically estimated for individuals aged 65 or older. Applying a consistent data set and methods across the six illness categories not only fills a gap in the literature, it also provides estimates that are directly comparable across the illness categories. Finally, these conditions were selected because many cases of these illnesses are potentially preventable through improvements in environmental conditions. All of the illnesses are known or strongly suspected to include environmental exposures as a significant risk factor.

Because these illnesses are often associated with exposure to environmental conditions, a specific objective of this analysis is to inform such efforts as the U.S. Environmental Protection Agency's (EPA) Aging Initiative, which was established in 2002 to study environmental health impacts among older persons and to help prioritize policies for mitigating these impacts (EPA, 2003). Although the burden of disease estimates developed in this analysis are not exclusively associated with environmental exposures, they do provide starting points (i.e., upper bounds) for evaluating the potentially avoidable costs of illness in the aged 65 or older population that would result from improved air, water, and general environmental quality in the United States.

Overview of Selected Health Conditions

First, a brief discussion is provided of the six health conditions with regard to their impact on older populations in the United States and their links to environmental exposures. The available evidence on costs of illness for each condition is also summarized. Although several studies have estimated costs for these conditions, few have specifically focused on the aged 65 or older population; and the variety of measurement approaches used makes it difficult to compare results across studies.

CLD, including asthma, emphysema, and other conditions classified as chronic obstructive pulmonary disease (COPD), affects millions of older adults (Lucas, Schiller, & Benson, 2004). Chronic lower respiratory diseases, in particular, are the fourth leading cause of death for persons aged 65 or older (NCHS, 2002). Exposures to common air pollutants, such as tobacco smoke, particulate matter (PM), and ozone, have been found in several studies to cause and/or exacerbate these conditions. For a summary of the epidemiological evidence regarding links between common air pollutants and respiratory and cardiovascular illness, see EPA (1999).

A number of studies have estimated costs for a range of different outcomes associated with CLD, including hospitalization costs, expenditures for all health care services, work-loss costs, employer costs for absenteeism and employees' health care services, and informal caregiving costs. Consequently, cost estimates also varied widely. Estimated annual costs per person for all health care services associated with CLD ranged from approximately \$1,000 to \$7,800 (Ray et al., 2000; Wilson, Devine & So, 2000). Please note that all dollar figures in this section have been converted to 2000 dollars using the Annual Medical Care Consumer Price Index. Aggregate annual health care expenditures associated with CLD were estimated to range from \$2.8 billion in direct costs for adults (aged 18 or older) with asthma to \$23.3 billion in direct costs for COPD (NHLBI, 1996; Wiess, Gergen, & Hodgson, 1992).

IHD, including heart attacks and angina pectoris, is among the most common conditions suffered by individuals aged 65 or older in the United States (Lucas et al., 2004). Diseases of the heart are also the leading cause of death among persons aged 65 or older, accounting for roughly 33% of deaths in this age group (NCHS, 2002). Several studies have also shown that exposures to common pollutants (e.g., PM) can increase risks associated with heart disease, and exposures to less common toxic pollutants (e.g., lead) have also been found to increase these risks (ATSDR, 1999; EPA, 1997 [Appendix G]; EPA, 1999).

Estimated costs for heart disease also vary widely. Estimated direct medical costs associated with heart disease ranged from \$5,900 to \$7,400 per person (Druss et al., 2001; Ray et al., 2000). Total estimated medical costs associated with heart disease ranged from \$67 billion for females aged 45 or older to more than \$100 billion for all circulatory diseases in persons aged 65 or older (Hoerger et al., 1999; Hodgson & Cohen, 1999). Large differences in estimated costs

arise primarily because of differences in the cost categories analyzed and in the age groups considered.

Stroke affects 2 to 3 million individuals aged 65 or older each year in the United States (Lucas et al., 2004). Cerebrovascular diseases, which include stroke, are the third leading cause of death in the United States among persons aged 65 or older (NCHS, 2002). Several studies have shown that exposures to pollutants, such as PM, ozone, and lead, increases risks of stroke-related deaths (ATSDR, 1999).

A few studies estimated the average costs related to hospitalization due to stroke in older populations. One study estimated average hospitalization costs for stroke for persons over the age of 65 that ranged from \$13,400 to almost \$63,000, depending on the type of stroke (Holloway, Witter, Lawton, Lipscomb & Samsa, 1996). Another study estimated hospital charges of approximately \$13,000 per person (aged 40 or older) for stroke alone (Mushinski, 1997). Other studies estimated total direct and indirect costs of stroke for persons of all ages to be approximately \$46 to \$47 billion per year (AHA, 2004; NCHS and NHLBI, 2000).

Lung cancers are the least prevalent of the six health conditions analyzed in this report; nevertheless, they have the second highest prevalence of cancers among persons aged 65 or older (Lucas et al., 2004). Moreover, these cancers are known to impose significant costs on a per-case basis. Links between environmental exposures and lung cancers are well established, with known or suspected environmental causes including exposures to PM (Pope et al., 2002), asbestos (ATSDR, 2001), and radon (ATSDR, 1990).

The estimated costs of lung cancers in the literature range from \$8.2 billion to \$32.5 billion per year using the broader definition of respiratory cancer (Brown & Fintor, 1995; Sullivan, Ramsey, & Lee, 2000). One study estimated average Medicare payments per year for

several cancers, including lung cancer, to be about \$28,000 per affected beneficiary (Riley, Potosky, Lubitz & Kessler, 1995).

Pneumonia is a relatively high-prevalence condition among older individuals; but more importantly, when older individuals are afflicted with this condition, they generally require more costly medical care than younger individuals. Pneumonia and influenza combined are the fifth leading cause of death among persons aged 65 or older (NCHS, 2002). As with CLD, exposures to common air pollutants, such as PM and ozone, have been found in several studies to cause and/or exacerbate pneumonia (EPA, 1999).

Pneumonia cost studies have primarily focused on hospitalization costs. Mean or median costs per hospitalization associated with pneumonia ranged from about \$5,900 to \$10,400 per person (Fine et al., 2000; Warren et al., 2003). Variations in these estimates reflect differences in the definitions used for pneumonia and the methods used (i.e., primary diagnosis costs versus attributable costs). Total direct medical cost estimates associated with pneumonia ranged from \$5.7 (for persons aged 65 or older) to \$19.4 billion per year (Niederman, McCombs, Unger, Kumar & Popovian, 1998; Thom, n.d.).

GI is common in all age groups in the United States; however, persons aged 65 or older face particularly high risks of hospitalization and death. For example, from 1979 to 1995, GI hospitalization rates for persons older than age 65 were more than twice as high as for younger persons. Exposures to waterborne pathogens are suspected to be significant contributors to overall rates of GI (Bennett, Holmberg, Rogers & Solomon 1987; Morris & Levin, 1995; Payment et al., 1991), although the attributable fraction is uncertain.

One study of GI-related costs used a disease classification approach similar to the one used in this analysis, which was specified to capture GI conditions most closely (although not

exclusively) associated with environmental exposures. Sandler et al. (2002) estimated direct medical costs associated with GI to be \$1.7 billion per year for all age groups and additional indirect costs of \$540 million per year. Just over half of these costs were estimated to result from foodborne illnesses.

METHODS

To assess the economic burden of the selected illnesses among older adults, we applied a cost-of-illness (COI) approach that measures both the direct and indirect costs of illness. Direct costs represent the dollar value of goods and services consumed as a result of illness and for which payment is made. These costs include payments for treatment, diagnosis, continuing care, rehabilitation, and terminal care. They are typically measured as costs related to hospital stays, physician services, nursing homes, prescription drugs, and in-home health care services. Indirect costs represent costs for which no payment changes hands but for which an economic effect is nonetheless observed. These costs include primarily productivity losses associated with illness and premature death; and they are typically measured as the value of lost productivity (labor and household) due to illness.

We applied a prevalence-based approach to estimate direct and indirect costs. Prevalence-based cost estimates include costs related to a condition for the prevalent population over a given period (usually a year). These estimates include costs for newly diagnosed cases as well as costs for persons in the later stages of disease. We provide estimated costs associated with each of the six selected health conditions among individuals aged 65 or older in the year 2000.

Below we describe the data sources and methods used to estimate the different components of direct and indirect costs. For each component, we applied a consistent set of data

and methods across the six health conditions. We defined each health condition in a consistent manner across data sources by using the same set of ICD-9 codes to identify service utilization and other costs for each condition: Chronic lung disease (491-4, 496), ischemic heart disease (410-4), stroke (430-4, 426), lung cancer (162.2-162.9, 197, 231), pneumonia (480-7), and gastrointestinal illness (001-009 [except 008.45], 558.9).

Direct Cost Estimation

To make best use of the available national data, we separated direct costs into two mutually exclusive components: medical costs and costs associated with self-administered prescription drugs. A third component of direct costs that is not fully captured by this analysis is the cost associated with nursing home care. We explored this issue by analyzing nursing home charges using the 1999 National Nursing Home Survey (NNHS). However, findings from NNHS indicated that none of the individual conditions had a meaningful or statistically significant impact on annual nursing home costs. Because of these findings, we did not include nursing home costs in the aggregate COI estimates.

Medical Costs

For individuals aged 65 or older, Medicare claims provide the most comprehensive source of data on costs for medical services. To access a nationally representative sample of these claims for 2000, we used data from the Consumer Assessment of Health Plans Surveys (CAHPS) for Medicare Fee-for-Service (MFFS) beneficiaries. The CAHPS-MFFS sample included 145,875 noninstitutionalized Medicare beneficiaries aged 65 or older. From this sample, we analyzed Medicare claims for five main categories of services: inpatient services, physician visits, outpatient services, home health care, and durable medical equipment. For each of the six health conditions and five medical service categories, claims were selected based on

their reported diagnosis codes. For inpatient services, we only selected claims recorded with a *primary* diagnosis matching one of the ICD-9 codes for the condition. For outpatient and home health services, for which Medicare claims do not report a primary diagnosis, we selected claims recorded with any diagnosis code matching the ICD-9 codes. For professional fees and durable medical equipment, there is a unique code for each claim.

Using these selected claims data, we estimated both the prevalence rate (number of cases per thousand individuals) and average cost (\$/case) of medical services for each condition. To estimate the total number of cases among the entire noninstitutionalized population of individuals aged 65 or older in 2000, we assumed that the estimated prevalence rates from CAHPS-MFFS were applicable to the entire population of approximately 33.5 million persons. To estimate the aggregate medical costs associated with these cases in 2000, we multiplied their number by the corresponding average medical cost estimates for each condition.

Costs for Self-Administered Drugs

Self-administered prescription drugs are not reimbursable by Medicare and are therefore not included in the claims-based cost estimates. To estimate these prescription drug costs for each of the six health conditions, we used data from the 2000 Medical Expenditures Panel Survey (MEPS), a nationally representative subsample of the National Health Interview Survey (NHIS). The 2000 MEPS requested information about the number of prescription medication purchases (including refills) and total expenditures for prescription drugs by sources of payment and by condition. We first calculated total prescription drug expenditures by condition for each individual aged 65 or older in the sample. We then calculated average prescription drug expenditures across all individuals with a given condition. Combining these average costs with

the prevalence estimates from the Medicare claims analysis, we estimated aggregate drug costs for each condition.

Indirect Cost Estimation

To estimate indirect costs for each condition, we applied a human-capital approach. This approach, commonly used in COI studies, measures the monetary value of time lost from work or household production activities because of excess morbidity or premature mortality. These productivity losses are estimated based on market earnings and an imputed value for household production.

Although the human-capital approach measures key components of the economic burden of illness on society, it has inherent limitations. For several reasons, indirect cost estimates based on this approach are best interpreted as lower-bound estimates for the full indirect costs of each condition. First, they do not include the value of time lost from consumption, leisure, or volunteer activities, all of which may be higher among older individuals. Second, they do not include the productivity or other losses incurred by informal caregivers. Third, they do not capture the costs of pain and suffering associated with an illness.

Furthermore, although the human-capital approach measures productivity losses due to premature mortality, these estimates should not be interpreted as measures of the full value of lost life. Rather, they estimate one component of the economic burden resulting from premature mortality. Primarily because of lower remaining life expectancy and labor force participation rates among older adults, these estimates tend to be lower for older adults. These results should not be interpreted to mean that the lives of older individuals are valued less by society.

Morbidity

Using data from the 2001 NHIS, we estimated the impact of specific health conditions on labor and household productivity among persons aged 65 or older. For labor productivity losses, we estimated the losses associated with being completely unable to work (out of the labor force) due to the health condition. These estimates were based respondents who reported that they were not currently working but did work previously. We estimated a probit model of not working for those who reported working previously and included controls for age and for three of the health conditions for which adequate data were reported: CLD, IHD, and stroke. The resulting probit model coefficients were used to calculate the marginal effect of having each of the three health conditions on the probability of not currently working for persons who reported working previously. The marginal effects are the estimates of the impact of each health condition on the probability of being unable to work because of the condition.

To estimate household productivity losses, we used a regression approach to analyze the determinants of the number of reported bed days by NHIS respondents aged 65 or older. By controlling for several other factors, including education, poverty status, self-reported health status, labor force participation status, and smoking status, the regression analysis allowed us to estimate the incremental effect of specific conditions on number of bed days. Based on these results, we predicted the average number of bed days attributable to each condition.

To estimate the dollar values associated with the changes in labor force participation and bed days attributable to each condition, we applied existing estimates of age-specific annual earnings and household productivity values for 2000. Using values reported in Grosse (2003), we calculated average annual labor force earnings of \$31,052 for individuals aged 65 or older who are in the labor force with positive earnings. The average annual value of household

services produced by persons aged 65 or older was estimated to be \$12,936, an average of \$35 per day.

Mortality

To assess mortality-related productivity losses, we used data from the 1998 National Vital Statistics Report (NVSR), which provides statistics on death rates in 1996 by age group and cause of death. The 1998 NSVR was the most recent NSVR that used ICD-9 codes to categorize causes of death and could therefore be most closely matched with the illness classification approach used in our analysis. We applied these rates to determine the number of annual deaths (by age groups) that are primarily associated with each of the six health conditions.

To estimate the dollar value of productivity losses associated with premature mortality, we multiplied the cause-specific and age-group-specific number of deaths for each health condition by estimates of age-group-specific present value of earnings (earnings and household production), which were also estimated by Grosse (2003). Because labor and household production estimates for the aged 85 or older group were not available for this analysis, we were not able to estimate mortality-related productivity losses for this group. Average productivity losses for persons aged 85 or older are expected to be relatively low compared with younger age groups; however, by not including values for this age group, we have underestimated total mortality-related losses for each condition.

RESULTS

Using the data and methods described above, we estimated the costs of illness associated with each of the six selected health conditions in 2000 among individuals aged 65 or older. These results are summarized below for each condition (in 2000 dollars). We first summarize the estimates of (1) rates of illness and mortality, and (2) average direct and indirect costs of

illness for each condition. We then combine these values and report the estimates of aggregate costs.

Prevalence and Average Direct Costs

Table 1 summarizes the estimates of the prevalence and the direct medical costs associated with the six health conditions based on the CAHPS-MFFS beneficiary data. The percent of beneficiaries aged 65 or older with each condition ranged from 1% for lung cancer to almost 18% for IHD. CLD and stroke had the second and third highest prevalence rates affecting, respectively, 11% and 7% of this population.

[Table 1 about here]

Although the prevalence of lung cancer was low among the aged 65 or older Medicare population, per capita medical costs were the highest of the six health conditions, at more than \$7,500 per case per year. This annual cost was over twice the estimated amount for the next highest cost illnesses—pneumonia, IHD, and stroke—which imposed direct medical costs of roughly \$3,000 per case per year. Also, GI was associated with the lowest average costs, at less than \$600 per case per year.

Although not reported in Table 1, the analysis of CAHPS-MFFS data also found the following for all six health conditions:

- Inpatient services accounted for the largest share of average medical costs (compared with physician, outpatient, home health, and durable medical equipment costs), ranging from 37% for CLD to 83% for pneumonia.
- Rates of illness were higher among persons aged 75 or older compared with persons aged 65 to 74. This difference was most notable for stroke and pneumonia, but was not statistically significant (at a 0.05 level) for lung cancer.

- Rates of illness were higher for males aged 65 or older than for females aged 65 or older (with the exception of GI, which had similar rates for males and females in this age group).

Using MEPS data as described above, we also estimated the average cost of self-administered prescription drugs for each condition. The number of MEPS respondents aged 65 or older who reported prescription medication purchases for lung cancer was too small to reliably include in this analysis; however, the numbers for the other conditions ranged from 114 respondents for stroke to 174 respondents for CLD. Based on these observations, we estimated average self-administered prescription drug costs ranging from \$35 per case per year for pneumonia and GI to \$363 per case per year for CLD.

Average Productivity Losses Due to Morbidity

Using data from the 2001 NHIS and from Grosse (2003), we estimated average morbidity-related labor productivity losses for three of the six health conditions. These results are presented in Table 2. Pneumonia and GI were not included in this part of the analysis because NHIS did not contain information about these illnesses. Of the 6,139 respondents aged 65 or older in the NHIS sample, approximately 8% indicated that they were unable to work but did work previously. Estimates of the impact of having each health condition on the probability of being unable to work, controlling for age and the other conditions, were 2% for IHD, 4% for CLD, and 6% for stroke. These estimated probabilities are presented in Table 2.

[Table 2 about here]

As shown in Table 2, the average earnings for individuals aged 65 or older—conditional on being in the labor force—is approximately \$31,000 per year. Multiplying the illness-specific incremental probability of being unable to work by the average conditional earnings provides an

estimate of the average productivity loss due to inability to work for individuals aged 65 or older who have the illness in question. These average annual labor productivity losses were estimated to range from \$621 per person with IHD to almost \$1,900 per person with stroke.

Using NHIS data, we also estimated household productivity losses for three of the six health conditions. We restricted the sample to all persons aged 65 or older, regardless of employment status, which resulted in a sample of 3,950 older adults. Because of the discrete nature of the variable of interest for this analysis (i.e., number of days spent in bed during the year), we used a negative binomial regression with a log link to estimate the determinants of bed days. The regression results are presented in Table 3. Controlling for sociodemographic characteristics—age, gender, education, income, work status, and race—and smoking status, the results indicate that CLD, heart disease, and stroke all have positive effects on the number of bed days experienced during the year. The effects of stroke and heart disease were found to be significant at a level < 0.01 , whereas CLD was significant at a 0.06 level.

[Table 3 about here]

Based on the regression results, we estimated the average number of bed days attributable to each health condition for individuals aged 65 or older. For each individual in the analysis sample with one of the conditions (525 with stroke, 749 with CLD, and 1,891 with IHD), we first used the regression results to estimate the difference in predicted bed days with and without the condition (i.e., calculating predicted bed days for condition=0 as compared with condition=1). We then estimated the average of these differences for each health condition subsample. The average number of bed days per year associated with each illness varied from 5 days per case of CLD to 8 days per case of IHD to 14 days per case of stroke. To estimate the indirect costs associated with each bed day, we assumed that they each resulted in one day of lost household

productivity. Based on estimates from Grosse (2003), the average value of household productivity for individuals aged 65 or older was equivalent to approximately \$35 per day in 2000. This estimate is based on the average time spent in household production (e.g., housework, yard maintenance, etc.), care providing, and personal care activities, each valued at the average market wage rate. Multiplying the average number of attributable bed days for each illness by this value produced estimates of average annual household productivity losses equal to \$185 per case of CLD, \$278 per case of IHD, and \$512 per case of stroke.

Average Productivity Losses Due to Mortality

To estimate the number of deaths in 2000 associated with each category of illness among individuals aged 65 or older, we applied age- and illness-specific mortality rates for 1996. In the 1998 NSVR, these rates were reported for three age groups of interest: 65 to 74, 75 to 84, and 85 or older. Assuming that the percentage of the population in each age group who died due to each illness did not change significantly from 1996 and 2000, we applied these percentages to the 2000 U.S. population in each age group to estimate the total number of deaths associated with each illness. These estimates are presented in Table 4. Of the six health conditions, IHD is responsible for the highest number of deaths in all three age categories, with an estimated total of almost 450,000 deaths among persons aged 65 or older. GI deaths account for by far the fewest number of estimated deaths (less than 1,000). Total deaths associated with each of the other four health conditions were estimated to fall between 80,000 and 160,000 in 2000.

[Table 4 about here]

To estimate productivity losses associated with these deaths, we again used results from Grosse (2003); however, in this case we used the average present value of future earnings and household production (assuming a 5 percent discount rate) for each age group. As shown in

Table 4, the present value of labor and household productivity that is lost due to premature death in 2000 is approximately \$190,000 for individuals aged 65 to 74 and \$94,000 for individuals aged 75 to 84. Unfortunately, present value estimates were not available for individuals aged 85 or older; therefore, total mortality-related productivity losses in this age group could not be calculated.

Aggregate Direct and Indirect Costs of Illness

Combining the estimated rates of morbidity and mortality with the average direct and indirect costs reported above, we estimated aggregate costs of illness for each of the six health conditions (see Table 5). First, to estimate the total number of cases of each illness, we applied the estimated prevalence rate from the Medicare beneficiary population aged 65 or older (see Table 1) to the entire aged 65 or older population in 2000 (33.5 million). The total number of deaths attributable to each illness was calculated by summing across the three age categories reported in Table 4. IHD accounts for both highest number of illnesses (over 6 million) and deaths. Lung cancers account for the fewest number of illnesses (355,000), but more deaths than CLD, pneumonia, or GI.

[Table 5 about here]

Aggregate direct costs for IHD were found to be significantly higher than for the other conditions. Cases of IHD among persons aged 65 or older were estimated to impose medical and drug costs of almost \$20 billion per year in 2000. By comparison, CLD, stroke, and pneumonia had direct cost estimates of between \$5 billion and \$10 billion. Due primarily to its low rate of prevalence, aggregate direct costs associated with lung cancer were estimated to be less than \$3 billion (although this estimate does not include drug costs), and for GI they were less than \$0.5 billion.

Aggregate indirect costs resulting from morbidity, which were estimated for three of the six health conditions (CHD, IHD, and stroke), were found in each case to be between \$5–6 billion per year. Due to data limitations, productivity losses could not be estimated for the other three conditions, which are less prevalent in the aged 65 or older population. Aggregate indirect costs associated with premature mortality were found to be highest for IHD (almost \$35 billion), followed by lung cancer (approximately \$15 billion), and CLD and stroke (both close to \$10 billion). Due to data limitations, none of these estimates includes mortality-related productivity losses among persons aged 85 or older. The resulting underestimation of productivity losses is largest in absolute terms for IHD because over 170,000 deaths are attributed to IHD among the aged 85 or older population (see Table 4) and largest in relative terms for pneumonia because more than 50% of pneumonia-caused deaths are from this age group.

Summing the direct and indirect cost estimates for each condition, the total estimated aggregate costs range from less than \$1 billion for GI to almost \$60 billion for IHD. The combined cost of these conditions among the aged 65 or older population in 2000 was estimated to be almost \$135 billion.

DISCUSSION

The population of older adults in the United States is expected to increase rapidly over the next 50 years. With this trend will come rising burdens of illness and increasing demands on the public health system. In this analysis, we examined the current aggregate cost burden imposed by six major health conditions among older adults, and estimated total direct and indirect costs of \$135 billion for 2001. With the aged 65 or older population expected to more than double by 2030, it would not be surprising to see these costs increase by a similar proportion.

Despite the magnitude of these estimated costs, it is important to emphasize that for several reasons they are best interpreted as lower-bound estimates of the total annual societal losses associated with the illnesses studied. First, a well-recognized limitation of the COI approach is that it cannot capture all of the relevant losses associated with illness, and for illnesses affecting older adults, this limitation is particularly important. The COI approach does not measure the (negative) value of pain and suffering for those directly or indirectly affected by the condition, nor does it capture the value of lost leisure time. Moreover, in cases where the conditions lead to premature mortality, the COI approach cannot measure the full value to society of avoiding those deaths. What the COI method does is measure the portion of economic losses that are most directly observable from available data on medical expenditures, labor market participation and earnings, and household production activities. These measurable losses represent a true burden on society, but they do not tell the entire story. For older adults who, on average, spend relatively less time in paid-labor activities and more time in leisure-related activities, unmeasured losses are likely to be particularly large.

Second, due to data limitations, this analysis does not include certain direct and indirect costs, such as nursing home costs, reductions in work days (as opposed to leaving the workforce), and mortality-related productivity losses for individuals aged 85 or older. These omitted costs are expected to be relatively small compared with the measured costs, but unfortunately they could not be reliably measured.

Third, estimating condition-specific medical costs based on Medicare claims data is complicated by the fact that inpatient services are often reported with more than one diagnosis. To estimate inpatient costs, we used a conservative approach that is likely to underestimate these costs. We only included costs if the condition of interest was listed as the primary diagnosis.

This approach includes some costs that may be associated with comorbid conditions, but it also omits a portion of the costs attributable to the condition of interest if the condition is secondary to the first reported diagnosis.

Given the magnitude of the current cost burden associated with these illnesses and the expectation that these costs will increase significantly as the U.S. population ages, it is particularly important to consider strategies for preventing these illnesses. Key among these strategies are policies to improve environmental health (one of the top 10 focus areas identified in *Healthy People 2010*). All of the six health conditions are known to be associated, at least in part, with environmental exposures, and older adults are often more susceptible than younger adults to environmental exposures. Therefore, improving air and water quality can play an important role in preventing and limiting the cost burden associated with these conditions in the aged 65 or older population. Future research should focus on understanding what proportion of the estimated costs of illness are specifically attributable to environmental exposures and to other preventable causes of illness.

ACKNOWLEDGMENTS

This study was funded by the U.S. Environmental Protection Agency's Aging Initiative through a subcontract with ICF Consulting, Inc. (Prime contract #: 68-W-02-045). We would like to thank Bill O'Neil for his helpful comments and suggestions.

REFERENCES

- Agency for Toxic Substance Disease Registry (ATSDR). (1990). Toxicological profile for radon. PB/91/180422/AS.
- Agency for Toxic Substance Disease Registry (ATSDR). (1999). Toxicological profile for lead. PB/99/166704.
- Agency for Toxic Substance Disease Registry (ATSDR). (2001). Toxicological profile for asbestos. PB/2001/109101.
- American Heart Association. Heart Disease and Stroke Statistics—2004 Update. Economic cost of cardiovascular diseases, from <<http://www.americanheart.org/presenter/jhtml?identifier=3000090>>.
- Bennett, J. V., Holmberg, S. D., Rogers, M. F., & Solomon, S. L. (1987). Infections and parasitic diseases. *American Journal of Preventive Medicine*, 3, 102–114.
- Brown, M. L., & Fintor, L. (1995). The economic burden of cancer. In P. Greenwald, B. S. Kramer, & D. L. Weed (Eds.), *Cancer prevention and control*. New York: Marcel Dekker (pp. 69–81). As cited in Kirschstein, R. (2000). *Disease-specific estimates of direct and indirect costs of illness and NIH support*. Washington, DC: Office of the Director, National Institutes of Health, Department of Health and Human Services.
- Druss, B. G., Marcus, S. C., Olfson, M., Tanielian, T., Elinson, L., & Pincus, H. A. (2001). Comparing the national economic burden of five chronic conditions. *Health Affairs (Millwood)*, 20(6), 233–241.

- Fine, M. J., Pratt, H. M., Obrosky, D. S., Lave, J. R., McIntosh, L. J., Singer, D. E., Coley, C. M., & Kapoor, W. N. (2000). Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. *American Journal of Medicine*, *109*(5), 378–385.
- Grosse, S. D. (2003). Productivity loss tables (Appendix). In A. C. Haddix, S. M. Teutsch, P., & S. Corso, (Eds.), *Prevention effectiveness: A guide to decision analysis and economic evaluation*. 2nd ed. London: Oxford University Press.
- Hodgson, T. A., & Cohen, A. J. (1999). Medical expenditures for major diseases, 1995. *Health Care Financing Review*, *21*(2), 119–164.
- Hoerger, T. J., Downs, K. E., Lakshmanan, M. C., Lindrooth, R. C., Plouffe, L., Wendling, B., West, S. L., & Oshfeldt, R. L. (1999). Health care use among U.S. women aged 45 and older: Total costs and costs for selected postmenopausal health risks. *Journal of Women's Health and Gender-Based Medicine*, *8*(8), 1077–1089.
- Holloway, R. G., Witter Jr., D. M., Lawton, K. B., Lipscomb, J., & Samsa, G. (1996). Inpatient costs of specific cerebrovascular events at five academic medical centers. *Neurology*, *46*(3), 854–860.
- Lucas, J. W., Schiller, J. S., & Benson, V. (2004). Summary health statistics for U.S. adults: National Health Interview Survey, 2001. National Center for Health Statistics. *Vital and Health Statistics* *10*(218).
- Morris, R. D., & Levin, R. (1995). Estimating the incidence of waterborne infectious disease related to drinking water in the United States. In *Assessing and managing health risks from drinking water contamination: Approaches and applications*. Proceedings of the Rome Symposium, September 1994.

- Mushinski, M. (1997). Variations in average charges for strokes and TIAs: United States, 1995. *Statistical Bulletin-Metropolitan Life Insurance Company*, 78(4), 9–18.
- National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (Thomas A. Hodgson) and National Heart, Lung, and Blood Institute (NHLBI), NIH (Thomas J. Thom). As cited in Kirschstein, R. (2000). *Disease-specific estimates of direct and indirect costs of illness and NIH support*. Washington, DC: Office of the Director, National Institutes of Health, Department of Health and Human Services.
- National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention. (2002). Deaths, percent of total deaths, and death rates for the 15 leading causes of death in selected age groups, by race and sex: United States, 1999-2001. Retrieved May 18, 2004, from http://www.cdc.gov/nchs/data/dvs/LCWK3_2000.pdf
- National Heart, Lung, and Blood Institute (NHLBI). (1996). Morbidity and mortality chartbook on cardiovascular, lung, and blood diseases. As cited in Kirschstein, R. (2000). *Disease-specific estimates of direct and indirect costs of illness and NIH support*. Washington, DC: Office of the Director. National Institutes of Health, Department of Health and Human Services.
- Niederman, M. S., McCombs, J. S., Unger, A. N., Kumar, A., & Popovian, R. (1998). The cost of treating community-acquired pneumonia. *Clinical Therapeutics*, 20(4):820–837.
- Payment, P., Richardson, L., Siemiatycki, J., Dewar, R., Edwardes, M., & Franco, E. (1991). A randomized trial to evaluate the risk of gastrointestinal disease due to consumption of drinking water meeting current microbiological standards. *American Journal of Public Health*, 81(6), 703–708.

- Pope, C. A., Burnett, R. T., Thun, M. J., Calle, E. E., Krewski, D., Ito, K., & Thurston, G. D. (2002). Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. *Journal of the American Medical Association*, 287(9), 1132–1141.
- Ray, G. T., Collin, F., Lieu, T., Fireman, B., Colby, C. J., Quesenberry, C. P., Van den Eeden, S. K., & Selby, J. V. (2000). The cost of health conditions in a health maintenance organization. *Medical Care Research and Review*, 57(1), 92–109.
- Riley, G. F., Potosky, A. L., Lubitz, J. D., & Kessler, L. G. (1995). Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. *Medical Care*, 33(8), 828–841.
- Sandler, R. S., Everhart, J. E., Donowitz, M., Adams, E., Cronin, K., Goodman, C., Gemmen, E., Shah, S., Avdic, A., & Rubin, R. (2002). The burden of selected digestive diseases in the United States. *Gastroenterology*, 122(5), 1500–1511.
- Sullivan, S. D., Ramsey, S. D., & Lee, T. A. (2000). The economic burden of COPD. *Chest*, 117(2 Suppl), 5S–9S.
- Thom, T. (n.d.). Unpublished estimates. As cited in Kirschstein, R. (2000). *Disease-specific estimates of direct and indirect costs of illness and NIH support*. Washington, DC: Office of the Director, National Institutes of Health, Department of Health and Human Services.
- U.S. Environmental Protection Agency (EPA). (1997). *The benefits and costs of the Clean Air Act, 1970 to 1990*. EPA 410-R-97-002. Washington, DC: Office of Air and Radiation.
- U.S. Environmental Protection Agency (EPA). (1999). *The benefits and costs of the Clean Air Act, 1990 to 2010*. EPA 410-R-99. Washington, DC: Office of Air and Radiation.

- U.S. Environmental Protection Agency. (2003). *Aging initiative: A national agenda for the environment and the aging*. Retrieved December 21, 2003, from <http://www.epa.gov/aging/pdfs/factsheet.pdf>
- Warren, D. K., Shukla, S. J., Olsen, M. A., Kollef, M. H., Hollenbeak, C. S., Cox, M. J., Cohen, M. M., & Fraser, V. J. (2003). Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. *Critical Care Medicine, 31*(5), 1312–1317.
- Wiess, K. B., Gergen, P. J., & Hodgson, T. A. (1992). An economic evaluation of asthma in the United States. *New England Journal of Medicine, 356*, 862–866.
- Wilson, L., Devine, E. B., & So, K. (2000). Direct medical costs of chronic obstructive pulmonary disease: Chronic bronchitis and emphysema. *Respiratory Medicine, 94*, 204–213.

Table 1. Prevalence and Average Direct Medical Costs for Six Health Conditions: Annual Medical Payments in 2000 for Medicare Beneficiaries Aged 65 or Older

| Health Condition | Beneficiaries with a Diagnosis | | | Direct Medical Costs | |
|--------------------------|---------------------------------------|----------------|---------------|-----------------------------|----------------|
| | Number | Percent | CI (±) | (\$/Case/Year) | |
| | | | | Mean | CI (±) |
| Chronic Lung Disease | 2,871,630 | 11 | (10.8, 11.1) | \$1,830 | (1,748, 1,913) |
| Ischemic Heart Disease | 4,696,071 | 18 | (17.7, 18.1) | \$3,003 | (2,880, 3,125) |
| Stroke | 1,924,797 | 7 | (7.2, 7.5) | \$2,812 | (2,653, 2,971) |
| Lung Cancer | 276,900 | 1 | (1.0, 1.1) | \$7,751 | (6,697, 8,534) |
| Pneumonia | 1,288,106 | 5 | (4.8, 5.0) | \$3,052 | (2,886, 3,218) |
| Gastrointestinal Illness | 588,371 | 2 | (2.2, 2.3) | \$579 | (522, 634) |

Note: Geographic weights used to obtain unbiased nationally representative estimates for Medicare 65+ population.

Table 2. Average Labor Productivity Losses Due to Inability to Work, by Health Condition

| Health Condition | Average Annual | | |
|-------------------------|--|--|--|
| | Estimated Probability of Being Unable to Work | Persons Aged 65 or Older in Labor Force | Earnings for Average Labor Productivity Loss (\$/Case/Year) |
| Chronic Lung Disease | 4% | \$31,052 | \$1,273 |
| Ischemic Heart Disease | 2% | \$31,052 | \$621 |
| Stroke | 6% | \$31,052 | \$1,894 |

Note: Estimates are in 2000 dollars and for persons aged 65 or older.

Table 3. Determinants of Bed Days: Negative Binomial Regression Results

| Independent Variable: Number of Bed Days in 2002 (N=3,950) | |
|---|--------------------------|
| Explanatory Variable | Coefficient |
| High school graduate | -0.16 |
| Female | 0.27 ^b |
| Low income (<200% of poverty line) | 0.03 |
| Middle income (<500% of poverty line) | 0.08 |
| High income (≥ 500% of poverty line) | -0.52 |
| Former smoker | 0.29 |
| Never smoked | 0.01 |
| Smoking status unknown | -25.08 ^a |
| Non-Hispanic white | -0.25 |
| Non-Hispanic black | 0.21 |
| Non-Hispanic other | 0.41 |
| Retired | 0.79 ^a |
| Not working but previously worked | 2.21 ^a |
| Never worked | 1.30 ^a |
| No functional limitation reported | -1.29 ^a |
| Age (in years) | 0.02 |
| <i>Self-report of CHRONIC LUNG DISEASE</i> | 0.408^b |
| <i>Self-report of HEART DISEASE</i> | 0.73^a |
| <i>Self-report of STROKE</i> | 0.81^a |
| Constant term | -0.65 |

Notes: All explanatory variables except constant term and age are indicator/dummy variables.

Reference case is Hispanic male, high school dropout, current smoker, with income below 100% of the poverty line, who currently works, and has a self-reported functional limitation, but does not have CLD, IHD, or stroke history.

^a denotes P-value based on robust standard errors < 0.05 .

^b denotes P-value based on robust standard errors < 0.10 and > 0.05 .

Table 4. Deaths and Mortality-Related Productivity Losses in 2000, by Health Condition

| Health Condition | Estimated Number of Deaths by Age Group | | | Average Mortality-Related Productivity Losses by Age Group ^a | | |
|--------------------------|---|----------|-------------|---|-----------|-------------|
| | 65 to 74 | 75 to 84 | 85 or older | 65 to 74 | 75 to 84 | 85 or older |
| | Chronic Lung Disease | 29,869 | 44,651 | 23,806 | \$190,000 | 94,000 |
| Ischemic Heart Disease | 97,226 | 169,993 | 176,275 | \$190,000 | 94,000 | n/a |
| Stroke | 25,053 | 59,972 | 70,975 | \$190,000 | 94,000 | n/a |
| Lung Cancer | 56,402 | 47,156 | 12,802 | \$190,000 | 94,000 | n/a |
| Pneumonia | 10,408 | 28,789 | 44,067 | \$190,000 | 94,000 | n/a |
| Gastrointestinal Illness | 98 | 212 | 263 | \$190,000 | 94,000 | n/a |

^a Average present value of future labor and household productivity.

n/a = not available.

Table 5. Estimated Cases and Aggregate Costs of Illness for Six Health Conditions Among Individuals Aged 65 or Older in 2000

| Health Condition | Cases (in thousands) | | Direct Costs (\$ millions) | | | Indirect Costs (\$ millions) | | | Total Costs |
|--------------------------|----------------------|--------|----------------------------|---------|----------|------------------------------|-----------|----------|---------------|
| | Illnesses | Deaths | Medical | Rx Drug | Subtotal | Morbidity | Mortality | Subtotal | (\$ millions) |
| Chronic Lung Disease | 3,685.8 | 98.3 | 6,745.0 | 1,337.0 | 8,082.0 | 5,374.6 | 9,895.8 | 15,270.5 | 23,352.5 |
| Ischemic Heart Disease | 6,027.5 | 443.5 | 18,100.7 | 1,648.8 | 19,749.5 | 5,416.2 | 34,535.8 | 39,951.9 | 59,701.4 |
| Stroke | 2,470.5 | 156.0 | 6,947.1 | 371.8 | 7,318.9 | 5,945.4 | 10,423.7 | 16,369.1 | 23,688.0 |
| Lung Cancer | 355.4 | 116.4 | 2,754.8 | n.e. | 2,754.8 | n.e. | 15,182.4 | 15,182.4 | 17,937.2 |
| Pneumonia | 1,653.3 | 83.3 | 5,045.9 | 57.3 | 5,103.2 | n.e. | 4,695.7 | 4,695.7 | 9,798.9 |
| Gastrointestinal Illness | 755.2 | 0.6 | 437.3 | 26.6 | 463.9 | n.e. | 38.7 | 38.7 | 502.5 |

n.e. = not estimated